News & Videos - TELIX PHARMACEUTICALS LIMITED - English

You are currently viewing all stock exchange news of the financial instrument TELIX PHARMACEUTICALS LIMITED regarding all markets in English.

> News03/21/2025 - 10:30 GlobeNewsWire published a news.

FDA Approves New Prostate Cancer Imaging Agent Gozellix® 03/21/2025 - 10:30• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging 1 agent for prostate cancer. Gozellix®, after radiolabeling with 68 Ga, is indicated...

Thank you Chart

> News03/17/2025 - 21:53 GlobeNewsWire published a news.

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America 03/17/2025 - 21:53• • GlobeNewsWire • Stocks

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection) the Company’s lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET 1 prostate cancer imaging agent to...

Thank you Chart

> News03/12/2025 - 22:41 GlobeNewsWire published a news.

Telix Adds Lead-212 Isotope Production Capability 03/12/2025 - 22:41• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 ( 212 Pb) and successfully completed first production. The new generator technology, developed internally by Telix’s IsoTherapeutics team, produces 212 Pb via a sealed Thorium-228 ( 228 Th) source, and significantly increases the...

Thank you Chart

> News03/03/2025 - 21:48 GlobeNewsWire published a news.

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum 03/03/2025 - 21:48• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers: Neeraj Agarwal, MD, Professor of...

Thank you Chart

> News02/25/2025 - 23:51 GlobeNewsWire published a news.

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review 02/25/2025 - 23:51• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET 1 imaging agent TLX250-CDx (Zircaix® 2 , 89 Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA 3 date of 27 August 2025, paving the way for a...

Thank you Chart

> News02/25/2025 - 12:30 GlobeNewsWire published a news.

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami 02/25/2025 - 12:30• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Center in Miami, FL, is recruiting and dosing patients in the ProstACT Global Phase 3 trial 1 of TLX591 for patients with advanced prostate cancer, as part of a wider United States (U.S.) roll-out. ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most...

Thank you Chart

> News02/20/2025 - 12:10 GlobeNewsWire published a news.

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion 02/20/2025 - 12:10• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise. FY2024 highlights Total revenue, driven primarily from sales of Illuccix ® of $783.2 million, up by 56% 1 from $502.5 million in 2023, beating full year guidance 2 . Second year of profitable growth, delivered in a period of...

Thank you Chart

> News02/13/2025 - 12:00 GlobeNewsWire published a news.

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025) 02/13/2025 - 12:00• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage and next generation therapeutic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA (US) from 13 – 15 February 2025. Dr. David N. Cade, Telix Group Chief Medical Officer, said, “Telix will...

Thank you Chart

> News02/12/2025 - 21:38 GlobeNewsWire published a news.

Illuccix® Approved in the United Kingdom 02/12/2025 - 21:38• • GlobeNewsWire • Stocks

MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET 1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization of prostate-specific...

Thank you Chart

> News01/30/2025 - 21:57 GlobeNewsWire published a news.

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform 01/30/2025 - 21:57• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities 1 . This...

Thank you Chart

> News01/27/2025 - 21:43 GlobeNewsWire published a news.

Telix Completes Acquisition of RLS (USA) Inc. 01/27/2025 - 21:43• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET 1 , SPECT 2 and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix’s presence in the United States (U.S.), with a network of over 30...

Thank you Chart

> News01/16/2025 - 22:06 GlobeNewsWire published a news.

Illuccix® Receives European Approval 01/16/2025 - 22:06• • GlobeNewsWire • Stocks

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET 1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final...

Thank you Chart

> News01/13/2025 - 21:35 GlobeNewsWire published a news.

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference 01/13/2025 - 21:35• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43 rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.). The presentation will take place this Wednesday, 15 January at 2:15 pm PST (5:15 pm EST / 9:15 am AEDT, 16 January). Participants can register for...

Thank you Chart

> News01/13/2025 - 07:08 GlobeNewsWire published a news.

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue 01/13/2025 - 07:08• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024). Sustained revenue growth Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million) 1 , represents an increase of 46% over the prior year corresponding quarter (Q4 2023: US$97 million or AU$148 million) and a...

Thank you Chart

> News01/12/2025 - 22:04 GlobeNewsWire published a news.

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform 01/12/2025 - 22:04• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities. This...

Thank you Chart

> News12/30/2024 - 20:45 GlobeNewsWire published a news.

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports 12/30/2024 - 20:45• • GlobeNewsWire • Stocks

MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx ( 99m Tc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports . The NOBLE ( Nob ody Le ft Behind) Registry (NOBLE) is a global real-world evidence (RWE) study that aims to improve equity of...

Thank you Chart

> News12/29/2024 - 21:53 GlobeNewsWire published a news.

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging 12/29/2024 - 21:53• • GlobeNewsWire • Stocks

MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix® 1 , 89 Zr- girentuximab) kidney cancer imaging 2 . TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell...

Thank you Chart

> News12/19/2024 - 12:00 GlobeNewsWire published a news.

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete 12/19/2024 - 12:00• • GlobeNewsWire • Stocks

MELBOURNE, Australia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses on-site from 2025 1 . The installation of cyclotrons from GE HealthCare and IBA (Ion Beam Applications S.A.), along with proprietary solid targets, establishes TMS...

Thank you Chart

> News11/18/2024 - 23:20 GlobeNewsWire published a news.

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline 11/18/2024 - 23:20• • GlobeNewsWire • Stocks

MELBOURNE, Australia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and...

Thank you Chart

> News11/13/2024 - 21:28 GlobeNewsWire published a news.

Telix ADSs Commence Trading on Nasdaq 11/13/2024 - 21:28• • GlobeNewsWire • Stocks

MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’. The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing. Each ADS represents one fully paid ordinary share of the Company. Telix...

Thank you Chart